tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Scorpion Stings D065008 1 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Retrognathia D063173 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Candidiasis, Invasive D058365 2 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Central Serous Chorioretinopathy D056833 1 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Netherton Syndrome D056770 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Invasive Pulmonary Aspergillosis D055744 1 associated lipids
Keratosis, Actinic D055623 3 associated lipids
Multiple Pulmonary Nodules D055613 2 associated lipids
Pancreatitis, Graft D055589 1 associated lipids
Failed Back Surgery Syndrome D055111 3 associated lipids
Primary Graft Dysfunction D055031 1 associated lipids
Idiopathic Interstitial Pneumonias D054988 1 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Precursor Cell Lymphoblastic Leukemia-Lymphoma D054198 10 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Mathieu C et al. Potential role of 1,25(OH)2 vitamin D3 as a dose-reducing agent for cyclosporine and FK 506. 1994 Transplant. Proc. pmid:7527950
Mueller AR et al. Severe neurotoxicity after liver transplantation: association between FK 506 therapy and hepatitis C virus disease. 1994 Transplant. Proc. pmid:7527951
Tai J et al. In vivo function of pig islet xenografts in immunosuppressed diabetic mice. 1995 Transplant. Proc. pmid:8539968
Ueki M et al. Functional and morphologic characterization of renal subcapsular islet isografts in rats treated with FK 506. 1994 Transplant. Proc. pmid:7513469
Schreier MH et al. Inhibition of T-cell signaling pathways by immunophilin drug complexes: are side effects inherent to immunosuppressive properties? 1993 Transplant. Proc. pmid:7679818
Tze WJ et al. Immunohistochemical studies of pig islet xenograft in rats immunosuppressed with FK 506. 1994 Transplant. Proc. pmid:7513470
Zheng B et al. Effects of the new and highly active immunosuppressant, rapamycin, on lymphoid tissues and cells in vivo. 1991 Transplant. Proc. pmid:1703717
Todo S et al. Early trials with FK 506 as primary treatment in liver transplantation. 1990 Transplant. Proc. pmid:1689886
Herrero JC et al. Role of immunosuppressive treatments based on mycophenolate mofetil in posttransplantation renal surgical complications. 2002 Transplant. Proc. pmid:11959201
Wachtman GS et al. Biologics and donor bone marrow cells for targeted immunomodulation in vascularized composite allotransplantation: a translational trial in swine. 2011 Transplant. Proc. pmid:22099837
Samuel D et al. Tacrolimus (FK506)-based dual versus triple therapy following liver transplantation. 1998 Transplant. Proc. pmid:9636563
Chakkera HA et al. Genetic differences in Native Americans and tacrolimus dosing after kidney transplantation. 2013 Jan-Feb Transplant. Proc. pmid:23375287
Tian Ch et al. B- and T-lymphocyte attenuator/herpes virus entry mediator as early indicators for acute rejection following kidney transplantation. 2013 Jan-Feb Transplant. Proc. pmid:23375291
Vilalta R et al. Delayed graft function is reduced with antithymocyte globulin induction in pediatric kidney transplantation. 2009 Jul-Aug Transplant. Proc. pmid:19715923
Fraile P et al. Non-skin solid tumors as a cause of morbidity and mortality after liver transplantation. 2009 Jul-Aug Transplant. Proc. pmid:19715943
Braun F et al. An ex vivo model to study the intestinal biotransformation of immunosuppressive drugs. 2000 Transplant. Proc. pmid:11120037
Žilinská Z et al. Impact of Trough Levels of Tacrolimus on Kidney Function and Graft Survival in Short and Longer Periods After Renal Transplantation. 2016 Transplant. Proc. pmid:27788794
Nakao A et al. Combined effect of donor-specific bone marrow transplantation via portal vein and FK506 on small bowel transplantation in the rat. 2000 Transplant. Proc. pmid:11120044
Reyes J et al. Nutritional management of intestinal transplant recipients. 1993 Transplant. Proc. pmid:7680149
Luk JM et al. Immunosuppressive effects of Tripterygium wilfordii polysaccharide on LPS-stimulated human monocytes. 2000 Transplant. Proc. pmid:11120045
Abu-Elmagd KM et al. Monitoring and treatment of intestinal allograft rejection in humans. 1993 Transplant. Proc. pmid:7680150
Undre NA et al. Pharmacokinetics of tacrolimus: clinically relevant aspects. 1999 Transplant. Proc. pmid:10576037
Farghali H et al. Effect of FK 506 chronic administration on bromosulphthalein hepatic excretion in rats. 1991 Transplant. Proc. pmid:1721283
Mayer AD Four-year follow-up of the European Tacrolimus Multicenter Renal Study. 1999 Transplant. Proc. pmid:10576038
Farghali H et al. A biochemical and 31P-NMR investigation of the effect of FK 506 and cyclosporine pretreatment on immobilized hepatocytes perifused with ethanol. 1991 Transplant. Proc. pmid:1721284
Pirenne J et al. Addition of the colon to small bowel grafts causes lethal graft-versus-host disease in FK 506-treated pigs. 1996 Transplant. Proc. pmid:8623447
Nishikawa S et al. Extended mycophenolate mofetil administration beyond day 30 in allogeneic hematopoietic stem cell transplantation as preemptive therapy for severe graft-versus-host disease. 2009 Transplant. Proc. pmid:19917404
Walker S et al. Clinical use and bioavailability of tacrolimus in heart-lung and double lung transplant recipients with cystic fibrosis. 1998 Transplant. Proc. pmid:9636618
Pérez-Flores I et al. Incidence and risk factors for the metabolic syndrome and posttransplant diabetes in renal transplant recipients taking tacrolimus. 2010 Transplant. Proc. pmid:20970565
Marzorati S et al. Effects of systemic immunosuppression on islet engraftment and function into a subcutaneous biocompatible device. 2009 Jan-Feb Transplant. Proc. pmid:19249555
Nardo B et al. Pretransplant xenogeneic blood transfusion combined with FK 506 prolongs hamster-to-rat liver xenograft survival. 1994 Transplant. Proc. pmid:7518112
Wiesner RH et al. Early cellular rejection treated with high-dose intravenous corticosteroid therapy is associated with a decrease in the incidence of steroid-resistant rejection and graft failure from rejection. 1993 Transplant. Proc. pmid:7682352
Bäckman L et al. Whole-blood and plasma levels of FK 506 after liver transplantation: results from the US Multicenter Trial. FK506 Multicenter Study Group. 1995 Transplant. Proc. pmid:7533361
Antoniou EA et al. Effect of donor-specific transfusion in combination with FK 506 in rat cardiac allotransplantation. 1999 Transplant. Proc. pmid:10578296
Zeevi A et al. Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin. 1991 Transplant. Proc. pmid:1721315
Erickson L et al. Gene expression profiling of acute rejection and mixed lymphocyte reaction with tacrolimus immunosuppression. 2002 Transplant. Proc. pmid:12176407
Iwahori T et al. Pharmacokinetic differences between morning and evening administration of cyclosporine and tacrolimus therapy. 2005 Transplant. Proc. pmid:15919450
Bismuth H Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group. 1995 Transplant. Proc. pmid:7533415
Nakamura K et al. The lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysis. 1991 Transplant. Proc. pmid:1721346
Ochiai T et al. Japanese multicenter studies of FK 506 in renal transplantation. Japanese FK 506 Study Group. 1995 Transplant. Proc. pmid:7533419
Jain AB et al. Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant. 1991 Transplant. Proc. pmid:1721347
Takaya S et al. Retransplantation of liver: a comparison of FK 506- and cyclosporine-treated patients. 1991 Transplant. Proc. pmid:1721348
Rabkin JM et al. Tacrolimus is associated with a lower incidence of cardiovascular complications in liver transplant recipients. 2002 Transplant. Proc. pmid:12176483
Deniz H et al. Inhibition of the renin angiotensin system decreases fibrogenic cytokine expression in tacrolimus nephrotoxicity in rats. 2006 Transplant. Proc. pmid:16549154
Oğütmen B et al. Transforming growth factor-beta1, vascular endothelial growth factor, and bone morphogenic protein-7 expression in tacrolimus-induced nephrotoxicity in rats. 2006 Transplant. Proc. pmid:16549155
Fisniku O et al. Protective effects of PG490-88 on chronic allograft rejection by changing intragraft gene expression profiles. 2005 Transplant. Proc. pmid:15919518
Branco KC et al. The impact of tacrolimus as rescue therapy in children using a double immunosuppressive regimen after heart transplantation. 2012 Transplant. Proc. pmid:23026625
Cotovio P et al. New-onset diabetes after transplantation: assessment of risk factors and clinical outcomes. 2013 Transplant. Proc. pmid:23622631
Valente G et al. Conversion from twice-daily to once-daily tacrolimus in stable liver transplant patients: effectiveness in a real-world setting. 2013 Transplant. Proc. pmid:23622676
Nishimoto Y et al. Real-time monitoring for detecting rejection using strain gauge force transducers in porcine small bowel transplantation. 2004 Transplant. Proc. pmid:15050153
Lyne JC et al. Cadaveric renal transplantation against a positive historic crossmatch under tacrolimus immunosuppression: long-term follow-up. 1997 Feb-Mar Transplant. Proc. pmid:9123015
Meçule A et al. Tacrolimus trough levels and level-to-dose ratio in stable renal transplant patients converted to a once-daily regimen. 2011 Transplant. Proc. pmid:21620042
Iaria G et al. Switch from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in kidney transplantation. 2011 Transplant. Proc. pmid:21620043
Sugitani A et al. Intestinal neurons in acute and chronic rejection after small bowel transplantation in dogs. 1996 Transplant. Proc. pmid:8907941
Takahara S et al. Monitoring of FK 506 blood levels in kidney transplant recipients. 1994 Transplant. Proc. pmid:7520623
Takayama K et al. Hepatocyte growth factor and vascular endothelial growth factor expression in pig-to-primate xenotransplanted hearts. 2000 Transplant. Proc. pmid:10936314
Yin DP et al. Efficacy of FK506, leflunomide, anti-CD4, and CTLA4IG treatments in rat to mouse pancreas xenograft transplantation. 2000 Transplant. Proc. pmid:10936320
Wagner K et al. Effect of FK 506 on excretion of urinary enzymes in rats. 1991 Transplant. Proc. pmid:1721379
Izbicki G et al. Improved survival after lung transplantation in patients treated with tacrolimus/mycophenolate mofetil as compared with cyclosporine/azathioprine. 2002 Transplant. Proc. pmid:12493439
Warty V et al. Distribution of FK 506 in plasma lipoproteins in transplant patients. 1991 Transplant. Proc. pmid:1703363
Witzigmann H et al. Immunosuppression with sirolimus/tacrolimus combination in pancreas transplantation: 1-year results. 2002 Transplant. Proc. pmid:12493472
Ushigome H et al. Immunosuppression in cadaveric renal transplant recipients from non-heart-beating donors in a single center. 2002 Transplant. Proc. pmid:12176533
Citterio F et al. Conversion to tacrolimus immunosuppression in renal transplant recipients: 12-month follow-up. 2002 Transplant. Proc. pmid:12176535
Weir M Impact of immunosuppressive regimes on posttransplant diabetes mellitus. 2001 Transplant. Proc. pmid:11498201
Kaibori M et al. Inhibition of iNOS induction by FK506, but not by cyclosporine, in rat hepatocytes. 1999 Feb-Mar Transplant. Proc. pmid:10083347
Personett HA et al. Impact of molecular adsorbent recirculating system therapy on tacrolimus elimination: a case report. 2014 Transplant. Proc. pmid:25017243
Ju MK et al. A 6-month, open-label, multicenter clinical study in Korean de novo renal transplant patients evaluating the efficacy, safety, and tolerance of myfortic concomitantly used with tacrolimus. 2012 Transplant. Proc. pmid:22310600
el-Ghoroury M et al. Efficacy and safety of tacrolimus versus cyclosporine in kidney and pancreas transplant recipients. 1997 Feb-Mar Transplant. Proc. pmid:9123461
Mueller AR et al. Long-term follow-up in hepatitis C patients with respect to immunosuppression. 1996 Transplant. Proc. pmid:8962255
Alessiani M et al. Pharmacokinetic study of intraarterial local intestinal infusion of tacrolimus. 2000 Transplant. Proc. pmid:10995915
Ricordi C et al. Human islet allotransplantation under FK 506. 1991 Transplant. Proc. pmid:1721410
Stütz A Immunosuppressive macrolides. 1992 Transplant. Proc. pmid:1379762
Harihara Y et al. Effects of interferon alpha/beta on cardiac allografts. 1996 Transplant. Proc. pmid:8658645
Beck Y and Akiyama N Effect of FK-506 and cyclosporine on human lymphocyte responses in vitro. 1989 Transplant. Proc. pmid:2472695
Molinaro M et al. Pharmacokinetics of tacrolimus during the early phase after heart transplantation. 2001 Transplant. Proc. pmid:11377570
van Riemsdijk IC et al. Improvement of cardiovascular risk factors in heart transplant recipients after conversion from cyclosporine to tacrolimus: a role of the TGF-beta system. 2002 Transplant. Proc. pmid:12176606
Pan D et al. Tacrolimus-associated Diffuse Gastrointestinal Ulcerations and Pathergy: A Case Report. Transplant. Proc. pmid:28104141
Dick TB et al. Fludrocortisone is effective in the management of tacrolimus-induced hyperkalemia in liver transplant recipients. 2011 Transplant. Proc. pmid:21911143
Abouljoud M et al. Conversion to neoral provides effective rescue therapy for liver and kidney transplant patients intolerant of Prograf. 2001 Feb-Mar Transplant. Proc. pmid:11267175
Zhou S et al. Tacrolimus enhances the invasion potential of hepatocellular carcinoma cells and promotes lymphatic metastasis in a rat model of hepatocellular carcinoma: involvement of vascular endothelial growth factor-C. 2011 Transplant. Proc. pmid:21911157
Lauro A et al. Liver transplantation for familial amyloid polyneuropathy non-VAL30MET variants: are cardiac complications influenced by prophylactic pacing and immunosuppressive weaning? 2005 Transplant. Proc. pmid:15964382
Zucker MJ et al. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis. 2005 Transplant. Proc. pmid:15964386
Hummel AD et al. Application of artificial neural networks in renal transplantation: classification of nephrotoxicity and acute cellular rejection episodes. 2010 Transplant. Proc. pmid:20304167
Berweck S et al. Clinical use of the euglycemic hyperinsulinemic clamp for diagnosis of tacrolimus-induced insulin resistance after combined pancreas-kidney transplantation. 1998 Transplant. Proc. pmid:9723345
Doesch AO et al. Increased adherence after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation: a pre-experimental study. 2010 Transplant. Proc. pmid:21168673
Collin C et al. Sublingual tacrolimus as an alternative to intravenous route in patients with thoracic transplant: a retrospective study. 2010 Transplant. Proc. pmid:21168693
Li ZY et al. Analytical performance of the Abbott Architect i2000 tacrolimus assay in Chinese patients after renal transplantation. 2010 Transplant. Proc. pmid:21168731
Dikow R et al. Blood pressure profile and treatment quality in liver allograft recipients-benefit of tacrolimus versus cyclosporine. 2004 Transplant. Proc. pmid:15251373
Yokomise H et al. Immunosuppressive effects of FK 506 in canine lung transplantation. 1991 Transplant. Proc. pmid:1721442
Hasegawa S et al. FK 506 and cyclosporine: effects and side effects in canine lung transplantation. 1991 Transplant. Proc. pmid:1721443
McCauley J et al. Renal transplantation under FK 506 in African-Americans: early experience. 1993 Transplant. Proc. pmid:7689270
Ochiai T et al. Histopathologic studies in renal transplant recipient dogs receiving treatment with FK-506. 1987 Transplant. Proc. pmid:2445085
Groth CG et al. New immunosuppressive drugs in transplantation. 1993 Transplant. Proc. pmid:7689274
Thiru S et al. Pathological studies in canine and baboon renal allograft recipients immunosuppressed with FK-506. 1987 Transplant. Proc. pmid:2445086
Groetzner J et al. Tacrolimus or cyclosporine for immunosuppression after cardiac transplantation: which treatment reveals more side effects during long-term follow-up? 2001 Feb-Mar Transplant. Proc. pmid:11267373
Reiner J et al. After Intestinal Transplantation Kidney Function Is Impaired by Downregulation of Epithelial Ion Transporters in the Ileum. 2016 Transplant. Proc. pmid:27109987
Chávez R et al. Hepatotrophic effect of cyclosporine and FK 506 is not mimicked by rapamycin. 1999 Transplant. Proc. pmid:10500655
Ginevri F et al. Expression of collagen by renal fibroblasts treated with FK 506 in vitro. 1998 Transplant. Proc. pmid:9636387
Carl S et al. Combining FK 506 and mycophenolate mofetil for the treatment of acute corticosteroid-resistant rejection following kidney transplantation: a new therapeutic concept. 1998 Transplant. Proc. pmid:9636502
Budde K et al. Tacrolimus rescue therapy in late rejection after renal transplantation: outcome after 18 months. 1998 Transplant. Proc. pmid:9636503